(Q38800053)

English

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

scientific article published on 18 February 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

phase II clinical trial

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

Olivier Trédan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

François-Clément Bidard

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

H Bonnefoi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

T Grellety

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

M Saghatchian

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

F Dalenc

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

A Mailliez

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

T L'Haridon

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

P Cottu

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

S Abadie-Lacourtoisie

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

B You

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

M Mousseau

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

J Dauba

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

F Del Piano

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

I Desmoulins

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

F Coussy

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

N Madranges

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

J Grenier

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

C Proudhon

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

G MacGrogan

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

C Orsini

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

M Pulido

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

A Gonçalves

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

18 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

812-818

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Identification of molecular apocrine breast tumours by microarray analysis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

A refined molecular taxonomy of breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Aromatase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Targeting androgen receptor in estrogen receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW067

21 January 2018

Identifiers

10.1093/ANNONC/MDW067

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052658%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38800053&oldid=2104629421"